Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus

Timothy Kottke, Feorillo Galivo, Phonphimon Wongthida, Rosa Maria Diaz, Jill Thompson, Dragan Jevremovic, Glen N Barber, Geoff Hall, John Chester, Peter Selby, Kevin Harrington, Alan Melcher, Richard G. Vile

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (IL-2) has been used in antitumor therapy, it is associated with endothelial cell injury, leading to vascular leak syndrome (VLS). Here, we demonstrate that IL-2-mediated VLS, accentuated by depletion of regulatory T cells (Treg), facilitates localization of intravenously (IV) delivered oncolytic virus into established tumors in immune-competent mice. IL-2, in association with Treg depletion, generates "hyperactivated" natural killer (NK) cells, possessing antitumor activity and secreting factors that facilitate virus spread/replication throughout the tumor by disrupting the tumor architecture. As a result, the combination of Treg depletion/ IL-2 and systemic oncolytic virotherapy was found to be significantly more therapeutic against established disease than either treatment alone. These data demonstrate that it is possible to combine biological therapy with oncolytic virotherapy to generate systemic therapy against established tumors.

Original languageEnglish
Pages (from-to)1217-1226
Number of pages10
JournalMolecular Therapy
Volume16
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Oncolytic Viruses
Interleukin-2
Oncolytic Virotherapy
Neoplasms
Blood Vessels
Therapeutics
Oncogenic Viruses
Architectural Accessibility
Biological Therapy
Regulatory T-Lymphocytes
Virus Replication
Natural Killer Cells
Endothelial Cells
Wounds and Injuries

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Kottke, T., Galivo, F., Wongthida, P., Maria Diaz, R., Thompson, J., Jevremovic, D., ... Vile, R. G. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Molecular Therapy, 16(7), 1217-1226. https://doi.org/10.1038/mt.2008.83

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. / Kottke, Timothy; Galivo, Feorillo; Wongthida, Phonphimon; Maria Diaz, Rosa; Thompson, Jill; Jevremovic, Dragan; Barber, Glen N; Hall, Geoff; Chester, John; Selby, Peter; Harrington, Kevin; Melcher, Alan; Vile, Richard G.

In: Molecular Therapy, Vol. 16, No. 7, 01.07.2008, p. 1217-1226.

Research output: Contribution to journalArticle

Kottke, T, Galivo, F, Wongthida, P, Maria Diaz, R, Thompson, J, Jevremovic, D, Barber, GN, Hall, G, Chester, J, Selby, P, Harrington, K, Melcher, A & Vile, RG 2008, 'Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus', Molecular Therapy, vol. 16, no. 7, pp. 1217-1226. https://doi.org/10.1038/mt.2008.83
Kottke, Timothy ; Galivo, Feorillo ; Wongthida, Phonphimon ; Maria Diaz, Rosa ; Thompson, Jill ; Jevremovic, Dragan ; Barber, Glen N ; Hall, Geoff ; Chester, John ; Selby, Peter ; Harrington, Kevin ; Melcher, Alan ; Vile, Richard G. / Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. In: Molecular Therapy. 2008 ; Vol. 16, No. 7. pp. 1217-1226.
@article{e83cd71fe95a4f00adb6b8eb8a306975,
title = "Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus",
abstract = "There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (IL-2) has been used in antitumor therapy, it is associated with endothelial cell injury, leading to vascular leak syndrome (VLS). Here, we demonstrate that IL-2-mediated VLS, accentuated by depletion of regulatory T cells (Treg), facilitates localization of intravenously (IV) delivered oncolytic virus into established tumors in immune-competent mice. IL-2, in association with Treg depletion, generates {"}hyperactivated{"} natural killer (NK) cells, possessing antitumor activity and secreting factors that facilitate virus spread/replication throughout the tumor by disrupting the tumor architecture. As a result, the combination of Treg depletion/ IL-2 and systemic oncolytic virotherapy was found to be significantly more therapeutic against established disease than either treatment alone. These data demonstrate that it is possible to combine biological therapy with oncolytic virotherapy to generate systemic therapy against established tumors.",
author = "Timothy Kottke and Feorillo Galivo and Phonphimon Wongthida and {Maria Diaz}, Rosa and Jill Thompson and Dragan Jevremovic and Barber, {Glen N} and Geoff Hall and John Chester and Peter Selby and Kevin Harrington and Alan Melcher and Vile, {Richard G.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1038/mt.2008.83",
language = "English",
volume = "16",
pages = "1217--1226",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus

AU - Kottke, Timothy

AU - Galivo, Feorillo

AU - Wongthida, Phonphimon

AU - Maria Diaz, Rosa

AU - Thompson, Jill

AU - Jevremovic, Dragan

AU - Barber, Glen N

AU - Hall, Geoff

AU - Chester, John

AU - Selby, Peter

AU - Harrington, Kevin

AU - Melcher, Alan

AU - Vile, Richard G.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (IL-2) has been used in antitumor therapy, it is associated with endothelial cell injury, leading to vascular leak syndrome (VLS). Here, we demonstrate that IL-2-mediated VLS, accentuated by depletion of regulatory T cells (Treg), facilitates localization of intravenously (IV) delivered oncolytic virus into established tumors in immune-competent mice. IL-2, in association with Treg depletion, generates "hyperactivated" natural killer (NK) cells, possessing antitumor activity and secreting factors that facilitate virus spread/replication throughout the tumor by disrupting the tumor architecture. As a result, the combination of Treg depletion/ IL-2 and systemic oncolytic virotherapy was found to be significantly more therapeutic against established disease than either treatment alone. These data demonstrate that it is possible to combine biological therapy with oncolytic virotherapy to generate systemic therapy against established tumors.

AB - There are several roadblocks that hinder systemic delivery of oncolytic viruses to the sites of metastatic disease. These include the tumor vasculature, which provides a physical barrier to tumor-specific virus extravasation. Although interleukin-2 (IL-2) has been used in antitumor therapy, it is associated with endothelial cell injury, leading to vascular leak syndrome (VLS). Here, we demonstrate that IL-2-mediated VLS, accentuated by depletion of regulatory T cells (Treg), facilitates localization of intravenously (IV) delivered oncolytic virus into established tumors in immune-competent mice. IL-2, in association with Treg depletion, generates "hyperactivated" natural killer (NK) cells, possessing antitumor activity and secreting factors that facilitate virus spread/replication throughout the tumor by disrupting the tumor architecture. As a result, the combination of Treg depletion/ IL-2 and systemic oncolytic virotherapy was found to be significantly more therapeutic against established disease than either treatment alone. These data demonstrate that it is possible to combine biological therapy with oncolytic virotherapy to generate systemic therapy against established tumors.

UR - http://www.scopus.com/inward/record.url?scp=45749096230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749096230&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.83

DO - 10.1038/mt.2008.83

M3 - Article

VL - 16

SP - 1217

EP - 1226

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 7

ER -